Researchers from Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Miramoon Pharma SL and affiliated organizations published the preclinical characterization ...
The oncoprotein transcription factor MYC is a major driver of malignancy and a highly validated but challenging target for the development of anticancer therapies. Novel strategies to inhibit MYC may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback